World Stroke Day - SVIN latest clinical trials and breaking science news

The Society of Vascular and Interventional Neurology (SVIN) would like to announce today on World Stroke Day that it stands committed to the advancement of scientific research to improve the lives of stroke (aka brain-attack) patients worldwide. Stroke and interventional neurologists, who are members of the SVIN, working collaboratively with interventional neuro-radiologists and endovascular neurosurgeons have played a pivotal role in clinical trials pioneering the use of clot retrieval devices, such as retrievable stents and vacuum aspiration devices, also referred to as stroke thrombectomy.

"This collaborative effort, with stroke surgeons worldwide, has led to the establishment of stroke thrombectomy as a standard of care for large vessel occlusion (LVO) stroke." explains Italo Linfante, MD FAHA FSVIN, current President of the SVIN. "We are at a very exciting phase in brain-attack care similar to heart-attack care in the mid-90's. The results of the latest clinical trials and breaking news on next-generation devices that can transform stroke thrombectomy in the next decade, will be among the key highlights at our upcoming annual meeting." summarizes Dr. Linfante.

In the past year, there have been two randomized clinical trials (ASTER and COMPASS) evaluating the role of vacuum aspiration for removing blood clots in LVO stroke patients. In addition, there have been two randomized clinical trials evaluating the role of stroke thrombectomy in extended treatment time windows (DAWN: within 6-24 hours and DEFUSE 3: within 6-16 hours of stroke onset) to benefit LVO stroke patients including those who wake up with a stroke.

"We are pleased to announce that the results of another landmark clinical trial for stroke thrombectomy, namely the POSITIVE Stroke Clinical Trial will be presented at the upcoming SVIN annual meeting." reiterates Ameer E. Hassan, DO FAHA FSVIN, Chair of SVIN's 2018 annual meeting. Lead authors Drs. J Mocco and Aquilla Turk, along with their POSITIVE trial collaborators will be presenting the results of the POSITIVE (PerfusiOn Imaging Selection of Ischemic STroke PatIents for EndoVascular ThErapy) Stroke Clinical Trial (ClinicalTrials.gov NCT01852201). This is a randomized clinical trial comparing endovascular treatment (stroke thrombectomy with vacuum aspiration or a retrievable stent, separately or in combination) versus best medical therapy in LVO stroke patients with appropriate imaging selection within 6-12 hours of stroke onset.

A panel of leading stroke experts rigorously reviewed over 150 scientific research submissions to select the latest clinical trials and breakthrough technology to be showcased at the SVIN's 2018 annual meeting. Thanh Nguyen, MD FRCPc FAHA FSVIN, Chair of SVIN's scientific research committee explains, "In addition to the latest clinical trials, we want to showcase the groundbreaking science behind the most innovative devices that have tremendous potential to improve stroke thrombectomy worldwide."

One such news is from lead authors Drs. Miklos Marosfoi and Matthew J. Gounis, who along with their collaborators at the University of Massachusetts, will be presenting foundational research on a new aspiration device platform that can offer cyclical vacuum aspiration (varying the vacuum suction intensity) as a means of improving clot ingestion into aspiration catheters. In addition, they will be presenting the role of cyclical vacuum aspiration in decreasing release of dangerous debris during stroke thrombectomy that could cause secondary stroke.

The SVIN 2018 Annual Meeting will be held November 14-17 in San Diego, California. "We are excited that stroke surgeons, clinical trialists, and innovators worldwide are choosing the SVIN annual meeting forum to present the results of the latest clinical trials and breaking news on next-generation technologies that can have a transformative impact on stroke thrombectomy and thereby improving the lives of stroke patients and their caregivers worldwide." concludes Dr. Linfante.

About SVIN

The Society of Vascular and Interventional Neurology was created to achieve the highest level of care for patients through increased collaboration in scientific research and by educating young professionals and training young investigators. The Society also aims to provide opportunities to connect leaders in the field and provide a common ground for dialogue and creation of practice and safety standards. Our mission is to represent the advancement of interventional neurology as a field with the ultimate goal of improving clinical care and outcomes of patients with stroke and cerebrovascular diseases.

The SVIN Annual Meeting is a premier academic venue with scientific presentations covering the full spectrum of cerebrovascular diseases and stroke. Participants have the opportunity to discuss embolectomy, aneurysms and AVMs, subarachnoid and intracranial hemorrhage, endovascular saves and innovative approaches, new device review, international perspectives, and other-related topics. The SVIN 2018 Annual Meeting will be held November 14-17 in San Diego, California. New for 2018, SVIN is pleased to announce a vascular neurology track, an advance practice provider track, a live Basic Stroke Emergency Support course, and a hands on fellows training course. Registration for the SVIN 2018 Annual Meeting is now open.

For further information about SVIN, please visit http://www.svin.org

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...